Hydrocortisone + Placebo
ApprovedTerminated 3 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Partial Corticotrope Insufficiency
Conditions
Partial Corticotrope Insufficiency
Trial Timeline
Feb 1, 2010 → Mar 1, 2015
NCT ID
NCT01089075About Hydrocortisone + Placebo
Hydrocortisone + Placebo is a approved stage product being developed by Novo Nordisk for Partial Corticotrope Insufficiency. The current trial status is terminated. This product is registered under clinical trial identifier NCT01089075. Target conditions include Partial Corticotrope Insufficiency.
What happened to similar drugs?
17 of 20 similar drugs in Partial Corticotrope Insufficiency were approved
Approved (17) Terminated (4) Active (3)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01089075 | Approved | Terminated |
Competing Products
20 competing products in Partial Corticotrope Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| perampanel + perampanel | Eisai | Phase 1 | 29 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Approved | 35 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 29 |
| perampanel | Eisai | Phase 2 | 35 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Perampanel + Placebo | Eisai | Phase 3 | 40 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 40 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 43 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Zonisamide + Placebo | Eisai | Phase 3 | 40 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Rufinamide | Eisai | Phase 3 | 32 |
| Zonisamide | Eisai | Phase 3 | 40 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 26 |